Phase Ib Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Sep 2017
At a glance
- Drugs Alpelisib (Primary) ; Enzalutamide (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 12 Sep 2017 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.
- 12 Sep 2017 Planned primary completion date changed from 1 Aug 2019 to 1 Dec 2019.
- 12 Sep 2017 Planned initiation date changed from 1 Aug 2017 to 1 Dec 2017.